News | June 26, 2014

Advanced Alumina Ceramic Finds Niche in Oncology Equipment

June 25, 2014 — Thanks to its excellent dielectric properties and a reliable surface finish, a high-quality alumina ceramic from Morgan Advanced Materials is now being successfully used in radiotherapy equipment for oncology treatment.

Deranox 970 is a high-density, non-porous and vacuum-tight material with a 97 percent aluminium oxide content, which provides excellent electrical insulation. It is frequently used in high-vacuum systems, in laser and microscope applications and as an insulator in medical and scientific equipment, and has now been specified as the sealing element for RF windows in radiotherapy equipment.

Acting as a mechanical seal at either end of the vacuum chamber through which electron beams pass in the radiotherapy process, RF windows maintain the integrity of the vacuum, allowing electrons to pass through while preventing both ingress of contaminants and vacuum leakage.

Yannick Galais from Morgan explained: “While most solutions for RF windows contain around 97 percent alumina, it is the remaining 3 percent that makes all the difference in dielectric performance. The alumina ceramic formulation of Deranox 970 provides a high dielectric constant — 9.85 and 9.84 at 2.8GHz and 2.9GHz respectively — and low loss tangent — 0.00109 and 0.00110 at 2.8GHz and 2.9GHz respectively. Externally tested and verified by an independent and fully accredited testing house to an internationally recognized standard, ASTM D2520, these properties contribute to excellent stability at high frequencies.

“Our sophisticated powder manufacturing processes provide excellent repeatability from batch to batch, between batches, which is a key parameter in tuning the nominal wavelength and beam frequency, which will ultimately determine the performance of the of the radiotherapy machine. Our precision machining capabilities guarantee a consistent surface finish and flatness preventing RF reflectance and thus eliminating heat and leakage over time. Providing an impurity-free surface finish also improves the performance of the radiotherapy machinery by removing any potential for oxidation on the RF window,” Galais said.

Using advanced simulation techniques and extensive modeling, Deranox 970 has been comprehensively tested for radiotherapy applications prior to the prototype stage to ensure its suitability — followed by in-depth real-life testing to ensure optimum performance within a very tight tolerance range. Developed alongside Deranox 970 for radiotherapy equipment, Morgan has also introduced a tailored moly-manganese metalizing ink to facilitate the bonding process when the RF window is brazed to the body of the machine, creating the optimum seal and safeguarding the vacuum. As each RF window is individually designed for specific machinery, Morgan’s inks are custom formulated for each material grade. In addition to the ceramic, Morgan is able to supply the complete RF window sub-assembly including mounting flanges. Innovative design features allow Morgan to offer ceramic RF windows brazed inside the oxygen free copper (OFC) vacuum chamber.

Galais continued, “RF windows made of Deranox 970 will last the lifetime of the radiotherapy equipment — generally 20 years plus. Within the highly time-sensitive oncology treatment pathway, disruption to therapy machinery is simply not an option and failure of an RF window will often require full replacement of the radiotherapy machine, at enormous cost to the hospital trust and causing unacceptable delays for patients. The purity of our Deranox 970 material, coupled with its reliable dielectric properties and Morgan’s extensive modeling and test processes, ensure a high-quality RF window solution with long-lasting performance.”

For more information: www.morganadvancedmaterials.com

Related Content

New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
News | Treatment Planning | May 24, 2018
Daniela Schmitt, Ph.D., took top honors in the overall category of the 2018 TROG Plan Study: Stereotactic Radiosurgery...
Overlay Init